Search
Ezogabine
go.drugbank.com/drugs/DB04953ApprovedWithdrawnFDA approved in June 10, 2011 under the name of ezogabine. … It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures
AG-702
go.drugbank.com/drugs/DB05836ExperimentalAG-702 is a recombinant human heat shock protein also known as stress protein. … It is also known as HSPs, which are a group of proteins that are induced when a cell undergoes various types of environmental stresses like heat, cold and oxygen deprivation.
Garadacimab
go.drugbank.com/drugs/DB15629Approved[A273993] In June 2025, garadacimab was approved by the US FDA for the prophylaxis of HAE episodes in patients ≥12 years of age. … [L53303,L53283] It is the first inhibitor of factor XIIa to receive market approval.[L53303]
Oxethazaine
go.drugbank.com/drugs/DB12532ApprovedWithdrawnOxetacaine, also called oxethazaince, is a potent surface analgesic with the molecular formula N, N-bis-(N-methyl-N-phenyl-t-butyl-acetamide)-beta-hydroxyethylamine that conserves its unionized form at … [L1113] It is also in the list of approved derivatives of herbal products by the EMA.[L2816]
Mixtures: MUCAINE 200 ML SUSPANSIYONCilastatin
go.drugbank.com/drugs/DB01597ApprovedInvestigationalCilastatin is an inhibitor of renal dehydropeptidase, an enzyme responsible for both the metabolism of thienamycin beta-lactam antibiotics as well as conversion of leukotriene D4 to leukotriene E4.
Mixtures: IMIPENEM E CILASTATINA SUN, IMIPENEM E CILASTATINA SUNSynonyms: (Z)-(S)-6-carboxy-6-[(S)-2,2-dimethylcyclopropanecarboxamido]hex-5-enyl-L-cysteineAC-100
go.drugbank.com/drugs/DB05671InvestigationalIt is being developed by Acologix, Inc. … AC-100 is a novel synthetic peptide derived from an endogenous human protein produced by bone and dental cells (a fragment from matrix extracellular phosphoglycoprotein).
CX-046684
go.drugbank.com/drugs/DB19414ApprovedIt is the active ingredient of the 2024-2025 formulation of Moderna's Spikevax vaccine.[L40074]
Sebetralstat
go.drugbank.com/drugs/DB18305ApprovedInvestigationalFood and Drug Administration approved sebetralstat on July 7, 2025, for treating acute HAE attacks in patients aged 12 years and older [L53533, L53538].
Binodenoson
go.drugbank.com/drugs/DB04853InvestigationalThis specificity allows Binodenoson to deliver - in a single injection - a more effective dose of medication with fewer side effects than current treatments, which typically require a 15-20 minute infusion
INKP-102
go.drugbank.com/drugs/DB05326ExperimentalINKP-102 is the next generation sodium phosphate tablet designed to aid bowl preparation before colonoscopy.